接受放疗的头颈癌患者的心血管风险与预防
该研究回顾性分析了2011至2013年间接受根治性或辅助性放(化)疗的头颈鳞状细胞癌患者,计算其Framingham风险评分。结果显示患者基线心血管风险高,喉癌患者风险高于其他部位,且许多患者未获得最佳预防治疗。
要点
- 头颈鳞癌患者基线心血管疾病风险高,诊断时23%已有心血管疾病。
- 喉癌患者Framingham风险评分高于其他部位(20.5% vs 14.4%)。
- 有心血管疾病者中41%未用抗血小板治疗,30%未用他汀;无心血管疾病者中34%有启动他汀指征。
核心结论
- 头颈鳞状细胞癌患者基线心血管疾病风险高,且许多患者未接受最佳的预防治疗。
研究设计与样本
- 回顾性分析2011年至2013年间接受根治性或辅助性放(化)疗的头颈鳞状细胞癌患者,共115例,以III/IV期为主,中位随访2年。
主要发现
- 诊断时23%的患者已有心血管疾病。
- 喉癌患者的Framingham风险评分高于其他部位(20.5% vs 14.4%)。
- 所有患者中24%在诊断时血压未控制。
- 已有心血管疾病的患者中,41%未服用抗血小板药物,30%未服用他汀类药物。
- 无心血管疾病的患者中,34%有启动他汀治疗的指征。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The underlying contributors to cardiovascular disease (CVD) in patients with head and neck squamous cell carcinoma (HNSCC) are poorly characterized. METHODS: Patients with HNSCC who underwent definitive or adjuvant (chemo)radiation between 2011 and 2013 were retrospectively reviewed. The 10-year risk estimates for a CVD event were calculated according to the Framingham Risk Score (FRS). RESULTS: One hundred fifteen patients with predominantly stage III/IV HNSCC had a median follow-up of 2 years. At diagnosis, 23% of patients had CVD. The FRS was higher among patients with laryngeal cancer versus other sites (20.5% vs 14.4%). Twenty-four percent of all patients had uncontrolled blood pressure at diagnosis. Among the patients with CVD, 41% were not taking antiplatelet therapy and 30% were not taking statin therapy. Thirty-four percent of patients without CVD had indications for initiating statin therapy. CONCLUSION: Patients with HNSCC have a high baseline CVD risk and many do not receive optimal preventive care. © 2016 Wiley Periodicals, Inc. Head Neck 39: 527-532, 2017.
引用
- Okoye CC, Bucher J, Tatsuoka C, et al. Cardiovascular risk and prevention in patients with head and neck cancer treated with radiotherapy. Head Neck. 2016. PMID: 28032680. doi:10.1002/hed.24646
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。